US biotech company Viela Bio bags Uplizna FDA approval for NMOSD
Uplizna FDA approval : US biotech company Viela Bio has secured approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease of the central nervous system (CNS). The approval of Uplizna is for neuromyelitis optica spectrum […]